Barriers and Breakthrough Pathways for Including Neurological Innovative Drugs in Commercial Health Insurance:Taking Disease-Modifying Drugs for Alzheimer's Disease as an Example
摘要
在多层次医疗保障体系建设背景下,商业健康保险正逐步成为承接高值创新药物的重要支付力量.2025年,首版《商业健康保险创新药品目录》(2025年)的发布为创新药物实现多元支付提供了制度支持.其中的抗肿瘤创新药物[尤其是嵌合抗原受体T细胞免疫治疗(CAR-T)]已被较广泛地纳入商业健康保险保障范围,但同样被纳入目录的阿尔茨海默病疾病修饰类药物在商业健康保险中的实际保障仍较为有限.本文梳理创新药物的商业健康保险政策及地方实践,以阿尔茨海默病为例,分析其商业健康保险保障困境及原因.阿尔茨海默病疾病修饰类药物具有患者基数大、适用人群高龄化、需长期持续用药、带病群体界定困难等特征,与商业健康保险风险可识别、成本可预测的经营逻辑存在结构性错配.同时,制药企业风险共担机制传导不畅、医疗机构药物准入约束、数据支撑不足及供需双方认知偏差等因素,进一步加大了保障落地阻力.基于此,本文建议完善商业健康保险创新药物政策落地机制,强化专病数据积累与精算支持,探索制药企业、保险机构、医疗机构与政府多方风险共担模式,推动保障关口前移,构建适配疾病风险特征的创新药物多元支付机制.
Against the backdrop of developing a multi-level medical security system,commercial health insurance is gradually becoming an important payer for high-value innovative drugs.In 2025,the release of the first edition of the commercial health insurance innovative drug list provided institutional support for diversified payment for innovative drugs.Among them,innovative anti-tumor drugs,especially chimeric antigen receptor T cell immuno-therapy(CAR-T),have been relatively widely included in commercial health insurance.However,disease-modifying drugs for Alzheimer's disease(AD),which are also included in the list,still have relatively limited actual coverage in commercial health insurance.This paper reviews commercial health insurance policies and local practices for innovative drugs.Taking AD as an example,it analyzes the coverage dilemmas and their causes in commercial health insurance.Disease-modifying drugs for AD are characterized by a large patient base,an elderly target population,long-term continuous medication,and difficulty in defining the affected population.These characteristics are structurally mismatched with the operating logic of commercial health insurance,which relies on identifiable risks and predictable costs.At the same time,factors such as poor transmission of risk-sharing mechanisms among pharmaceutical companies,constraints on drug access in medical institutions,insufficient data support,and cognitive biases between supply and demand sides have further increased the resistance to coverage implementation.Based on this,this paper recommends improving the implementation mechanism of commercial health insurance innovative drug policies,strengthening disease-specific data accumulation and actuarial support,exploring a multi-party risk-sharing model involving pharmaceutical companies,insurers,medical institutions,and the government,and promoting the advancement of the coverage threshold to build a diversified payment mechanism for innovative drugs that fits the risk characteristics of the disease.